Native CD19 antibodies reveal a beneficial pharmacokinetic profile with long serum half-lives and low off-target toxicity, but a clinical pilot study using a mouse CD19-IgG2a antibody showed a limited response in B-cell non-Hodgkin’s lymphoma patients, probably due to limited effector functions elicited by the native CD19 antibody [16]. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.